Get the Stockscreener App
0.35
1.41%
-0.005
Pre-market:
.36
0.01
+2.86%
Reviva Pharmaceuticals Holdings Inc stock is traded at $0.35, with a volume of 2.88M.
It is down -1.41% in the last 24 hours and down -47.39% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$0.355
Open:
$0.3546
24h Volume:
2.88M
Relative Volume:
0.40
Market Cap:
$40.90M
Revenue:
-
Net Income/Loss:
$-27.11M
P/E Ratio:
-0.5385
EPS:
-0.65
Net Cash Flow:
$-26.55M
1W Performance:
+1.10%
1M Performance:
-47.39%
6M Performance:
-18.47%
1Y Performance:
-77.85%
1-Day Range:
$0.3333
$0.3559
1-Week Range:
$0.321
$0.39
52-Week Range:
$0.25
$2.15
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.35 | 41.48M | 0 | -27.11M | -26.55M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Sentiment Watch: How sensitive is Reviva Pharmaceuticals Holdings Inc Equity Warrant to inflationEarnings Growth Report & Stepwise Trade Signal Guides - baoquankhu1.vn
Sectors Review: Will Reviva Pharmaceuticals Holdings Inc benefit from green energy policiesJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Levels: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant stock a top pick in earnings season2025 Fundamental Recap & Low Drawdown Momentum Ideas - Bộ Nội Vụ
Breakouts Watch: How Reviva Pharmaceuticals Holdings Inc stock reacts to Fed rate cutsWeekly Stock Analysis & Community Consensus Trade Alerts - Bộ Nội Vụ
Profit Recap: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant withstand a market correctionAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far - Finviz
Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026 - Yahoo Finance
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock deliver sustainable ROEQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock a top pick in earnings seasonJuly 2025 Weekly Recap & High Conviction Trade Alerts - Улправда
Aug Opening: How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
symbol__ Stock Quote Price and Forecast - CNN
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoptionRate Cut & Entry and Exit Point Strategies - Улправда
Is Reviva Pharmaceuticals Holdings Inc. stock trading near support levels2025 Market Outlook & High Yield Equity Trading Tips - Улправда
How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingTrade Volume Report & Smart Allocation Stock Tips - Улправда
Reviva Pharmaceuticals Holdings, Inc. Announces Publication on Clinical Vocal Biomarker Data from the Recover Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - marketscreener.com
Aug PreEarnings: How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoption2025 Macro Impact & Weekly Chart Analysis and Trade Guides - Улправда
Will Reviva Pharmaceuticals Holdings Inc. stock maintain dividend yield2025 Retail Activity & Daily Profit Maximizing Trade Tips - Улправда
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - The Manila Times
Reviva Announces Publication on Clinical Vocal Biomarker - GlobeNewswire
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increases - Улправда
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendBlue Chip Stock Analysis & Free Long-Term Investment Planning - Улправда
Worth Investment Trading Company Limited Shows Risk Reward Favoring Upside - Early Times
Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating - Investing.com Canada
Volatility Watch: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant stock attract ESG investorsJuly 2025 Chart Watch & Verified Stock Trade Ideas - Bộ Nội Vụ
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Relief Rally in Veeram Securities Limited Stock Can It HoldVolatility Adjusted Trading & Download Our Free Trading Blueprint - earlytimes.in
What analysts say about Reviva Pharmaceuticals Holdings Inc stockBollinger Bands Signals & Try Our Free Strategy Builder Now - earlytimes.in
Technical Charts Suggest Momentum Shift in Sapphire Foods India LimitedEarnings Forecast Updates & Learn to Trade with Real-Time Feedback - earlytimes.in
Largest borrow rate increases among liquid names - TipRanks
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - The Manila Times
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Sahm
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
D Boral Capital maintains Reviva Pharmaceuticals Holdings (RVPH) buy recommendation - MSN
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Nigeria
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock: plunges 50% after FDA calls for second Phase 3 schizophrenia trial - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Nigeria
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):